IL241917B - Formulations for subcutaneous administration of furosemide - Google Patents

Formulations for subcutaneous administration of furosemide

Info

Publication number
IL241917B
IL241917B IL241917A IL24191715A IL241917B IL 241917 B IL241917 B IL 241917B IL 241917 A IL241917 A IL 241917A IL 24191715 A IL24191715 A IL 24191715A IL 241917 B IL241917 B IL 241917B
Authority
IL
Israel
Prior art keywords
furosemide
pharmaceutical formulations
subcutaneous administration
subcutaneous
administration
Prior art date
Application number
IL241917A
Other languages
English (en)
Hebrew (he)
Inventor
A Michaels Scott
Muntendam Pieter
Larsen Glen
Original Assignee
A Michaels Scott
Muntendam Pieter
Larsen Glen
Scpharmaceuticals Inc
Sc pharmaceuticals inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A Michaels Scott, Muntendam Pieter, Larsen Glen, Scpharmaceuticals Inc, Sc pharmaceuticals inc filed Critical A Michaels Scott
Publication of IL241917B publication Critical patent/IL241917B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL241917A 2013-04-05 2015-10-06 Formulations for subcutaneous administration of furosemide IL241917B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361808962P 2013-04-05 2013-04-05
PCT/US2014/032800 WO2014165660A1 (en) 2013-04-05 2014-04-03 Pharmaceutical formulations for subcutaneous administration of furosemide

Publications (1)

Publication Number Publication Date
IL241917B true IL241917B (en) 2020-10-29

Family

ID=51659206

Family Applications (1)

Application Number Title Priority Date Filing Date
IL241917A IL241917B (en) 2013-04-05 2015-10-06 Formulations for subcutaneous administration of furosemide

Country Status (14)

Country Link
US (5) US9884039B2 (https=)
EP (3) EP2981258B8 (https=)
JP (2) JP6415535B2 (https=)
KR (2) KR102493735B1 (https=)
CN (1) CN105431145B (https=)
AU (1) AU2014248164B2 (https=)
CA (1) CA2908935C (https=)
DK (1) DK2981258T3 (https=)
ES (1) ES2823589T3 (https=)
IL (1) IL241917B (https=)
MX (1) MX367165B (https=)
PT (1) PT2981258T (https=)
SG (2) SG11201508251RA (https=)
WO (1) WO2014165660A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2981258T (pt) * 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
DE102014115951A1 (de) 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
ES3041602T3 (en) 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US12397005B2 (en) 2019-01-04 2025-08-26 Sq Innovation Ag Pharmaceutical compositions of torsemide and uses thereof
PH12021551811A1 (en) 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
WO2022031959A1 (en) 2020-08-05 2022-02-10 Scpharmaceuticals Inc. Methods of treatment using furosemide
JP2024512650A (ja) 2021-04-02 2024-03-19 エスシーファーマシューティカルズ インコーポレイテッド フロセミドの皮下注入

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663348A (en) * 1985-07-02 1987-05-05 Warner-Lambert Co. Furosemide salts and pharmaceutical preparations thereof
US4698361A (en) 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
WO1992021769A1 (en) * 1991-05-30 1992-12-10 Abbott Laboratories Reagents containing a nonspecific binding blocker in ion-capture binding assays
US5633240A (en) * 1994-09-01 1997-05-27 Academic Pharmaceuticals Parenteral solutions containing metolazone
EP0808171A2 (en) * 1995-02-10 1997-11-26 G.D. SEARLE & CO. Combination of angiotensin converting enzyme inhibitor, side-effect-reduced amount of aldosterone antagonist and diuretic
IT1283608B1 (it) * 1996-04-17 1998-04-22 Ricerche Di Schiena Snc Di Dr Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
CN1068778C (zh) * 1998-05-15 2001-07-25 赵超英 救治用的药物组合物及其制备方法
ATE409280T1 (de) 2005-12-28 2008-10-15 Sensile Pat Ag Mikropumpe
MX2009000385A (es) * 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
EP2022518A1 (en) 2007-08-07 2009-02-11 Sensile Pat AG Modular drug delivery device for administering discrete doses of a medicament
US7923447B2 (en) * 2008-03-17 2011-04-12 Academic Pharmaceuticals Incorporated Parenteral solutions containing metolazone
CA2724540C (en) 2008-05-16 2014-07-08 Corthera, Inc. Treating dyspnea associated with acute heart failure with relaxin
EP2334302B1 (en) * 2008-09-09 2018-03-21 Cima Labs Inc DOSAGE FORMS FOR ACTIVE INGREDIENTS THAT ARE LOWLY IONIZABLE
US20110060280A1 (en) * 2009-09-04 2011-03-10 Sean Caffey Adhesive skin patch with pump for subcutaneous drug delivery
AU2012325801B2 (en) 2011-10-19 2016-05-12 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
PT2981258T (pt) 2013-04-05 2020-10-19 Scpharmaceuticals Inc Formulações farmacêuticas para administração subcutânea de furosemida
ES3041602T3 (en) * 2018-12-10 2025-11-13 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
US11246851B2 (en) * 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
PH12021551811A1 (en) * 2019-01-31 2022-03-21 Scpharmaceuticals Inc Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
US12042709B1 (en) * 2022-02-22 2024-07-23 Craig E. Williams Fighting training device

Also Published As

Publication number Publication date
CN105431145B (zh) 2019-12-10
EP2981258A1 (en) 2016-02-10
BR112015025204A2 (pt) 2021-03-16
JP6415535B2 (ja) 2018-10-31
EP2981258B8 (en) 2020-11-11
US11433044B2 (en) 2022-09-06
US12370168B2 (en) 2025-07-29
MX2015014064A (es) 2017-04-13
US20160051507A1 (en) 2016-02-25
CN105431145A (zh) 2016-03-23
US20230201156A1 (en) 2023-06-29
DK2981258T3 (da) 2020-10-19
EP4696308A1 (en) 2026-02-18
KR102493735B1 (ko) 2023-01-30
HK1221152A1 (zh) 2017-05-26
JP6677779B2 (ja) 2020-04-08
AU2014248164B2 (en) 2019-05-23
MX367165B (es) 2019-08-07
KR20160014592A (ko) 2016-02-11
PT2981258T (pt) 2020-10-19
US9884039B2 (en) 2018-02-06
US20250339397A1 (en) 2025-11-06
WO2014165660A1 (en) 2014-10-09
JP2019001821A (ja) 2019-01-10
EP2981258A4 (en) 2016-10-05
EP3799869A1 (en) 2021-04-07
EP2981258B1 (en) 2020-08-12
EP3799869B1 (en) 2025-08-27
KR20210075211A (ko) 2021-06-22
SG10201709388QA (en) 2017-12-28
US20180303790A1 (en) 2018-10-25
CA2908935A1 (en) 2014-10-09
ES2823589T3 (es) 2021-05-07
KR102266460B1 (ko) 2021-06-17
US20200038364A1 (en) 2020-02-06
JP2016515623A (ja) 2016-05-30
AU2014248164A1 (en) 2015-10-15
US10272064B2 (en) 2019-04-30
CA2908935C (en) 2021-06-15
SG11201508251RA (en) 2015-11-27

Similar Documents

Publication Publication Date Title
EP3082817A4 (en) Compositions for drug administration
ZA201504582B (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP4005604B8 (en) Delivery of drugs
IL240797B (en) Oral formulations of deferasirox
IL241917B (en) Formulations for subcutaneous administration of furosemide
SG11201604706TA (en) Stabilized pharmaceutical formulations of insulin aspart
PT2968368T (pt) Administração craniana de substâncias farmacêuticas
ZA201507576B (en) Pharmaceutical combination drug
AP2015008208A0 (en) Pharmaceutical administration forms comprising
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
DK2964193T3 (da) Lægemidler til oral indgivelse
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
GB201318686D0 (en) Pharmaceutical preparations
EP2958593A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TRANSMUCOSAL ADMINISTRATION OF BENZODIAZEPINES
GB201301721D0 (en) Pharmaceutical Preparations
SMT202500160T1 (it) Preparazione farmaceutica di carboidrati per uso terapeutico
GB201319437D0 (en) Delivery of drugs
SG10201913433SA (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
HUE047749T2 (hu) Gyógyszereket alacsony dózisban tartalmazó gyógyászati készítmények
SMT201900538T1 (it) Forme di dosaggio per la somministrazione orale di sostanze attive
GB201307659D0 (en) Preparation of drug particles by micronisation
IL244316A0 (en) A new composition of a drug
GB201318635D0 (en) Preservative free pharmaceutical compositions for ophthalmic administration
UA25230S (uk) Медичний пристрій для введення лікувальних препаратів

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed